This randomized clinical trial compares the effects of a technology-enhanced vs a standard behavioral weight loss intervention on achieving weight loss over 24 months among adults.
This meta-analysis summarizes published evidence about the prevalence of mental health conditions in patients undergoing bariatric surgery and associations between those conditions and weight loss outcomes.
This randomized trial reports that, among overweight and obese participants with type 2 diabetes, use of daily liraglutide, a glucagon-like peptide 1 analog, resulted in weight loss over 56 weeks compared with placebo.
This systematic review of 12 articles involving overweight or obese patients found that intensive behavioral counseling induced weight loss. Although little evidence suggests that such counseling is provided by primary care practitioners, trained interventionists could treat patients in the primary care setting.
Johnston and coauthors report the results of a meta-analysis comparison of weight loss among named diet programs in overweight and obese adults.
Kushner and Ryan review current best practices for assessment and lifestyle management of obesity and describe how updated guidelines can be applied to individual patients.
Ikramuddin and coauthors found that the use of vagal verve block therapy to treat morbidly obese patients proved more effective than a sham device but did not reach statistical superiority and was associated with more adverse effects than the sham device.
Puzziferri and coauthors assessed the quality of evidence and treatment effectiveness after bariatric procedures for weight loss, type 2 diabetes, hypertension, and hyperlipidemia in severely obese adults by reviewing clinical studies that had more than 2 years of outcome information and follow-up measures for at least 80% of the initial cohort.
Because 36% of US adults are obese with many unable to lose weight to improve health, Yanovski and Yanovski systematically review medications currently approved for obesity treatment and discuss off-label use of medications studied for obesity and use of obesity medications in clinical practice.
In a randomized clinical trial examining weight reduction and management of cardiometabolic risk factors in overweight and obese individuals with atrial fibrillation, Abed and colleagues measured atrial fibrillation symptoms in 150 patients for a median 15 months of follow-up.
To determine the effects of weight loss on patients with knee osteoarthritis, Messier and coauthors conducted a 18-month randomized clinical trial comparing 3 interventions—intensive diet-induced weight loss plus exercise, intensive diet-induced weight loss, and exercise—among 454 overweight and obese older community-dwelling adults.